Immunogenicity and efficacy of a measles virus-vectored chikungunya vaccine in nonhuman primates

Keyphrases

• Immunogenicity 100%
• Nonhuman Primate 100%
• Measles Virus 100%
• Chikungunya Fever 100%
• Chikungunya Vaccine 100%
• Viremia 75%
• Chikungunya Virus (CHIKV) 75%
• Fever 50%
• Titer 50%
• Macaque 50%
• Enzyme-linked Immunosorbent Assay (ELISA) 25%
• White Blood Cell Count 25%
• Human Health 25%
• Sham 25%
• Vaccination 25%
• Antibody Response 25%
• Blood Cells 25%
• Neutralizing Antibodies 25%
• Primates 25%
• Phase III Clinical Trial 25%
• Self-limiting 25%
• Blood Biochemistry 25%
• Nonhuman Primate Model 25%
• Cynomolgus Macaque 25%
• Virus Strains 25%
• Measles 25%
• Core Body Temperature 25%
• Chikungunya Virus Infection 25%
• Acute Febrile Illness 25%
• Viral-vectored Vaccine 25%
• Temperature Cell 25%

Immunology and Microbiology

• Immunogenicity 100%
• Chikungunya virus 100%
• Measles virus 100%
• Viremia 75%
• Titer 50%
• Macaca 50%
• Cytokine 25%
• Enzyme-Linked Immunosorbent Assay 25%
• Antibody Response 25%
• Viral Disease 25%
• Leukocyte Count 25%
• Hemocyte 25%
• Neutralizing Antibody 25%
• Macaca fascicularis 25%
• Virus Strain 25%
• Measles 25%
• Acute Febrile Illness 25%
• Core Temperature 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Immunogenicity 100%
• Chikungunya 100%
• Measles virus 100%
• Viremia 37%
• Chikungunya virus 37%
• Macaca 25%
• Clinical Trial 12%
• Diseases 12%
• Cytokine 12%
• Enzyme-Linked Immunosorbent Assay 12%
• Macaca fascicularis 12%
• Neutralizing Antibody 12%
• Measles 12%
• Virus Strain 12%